合作
Eli Lilly to buy Sangamo's gene-editing platforms and prion program in bankruptcy asset sale
In a court-supervised bankruptcy sale, Eli Lilly will pay $50 million for Sangamo's zinc finger, capsid delivery and molecular integrase platforms plus its prion disease program, while PTC Therapeutics takes the Fabry gene therapy for $111 million upfront plus up to $100 million in milestones. The sales remain subject to final court approval, with Sangamo set to receive around $163.55 million plus potential milestones.
文章預覽
SUBSCRIBE Menu SUBSCRIBE Show Search Search Query Submit Search News Business Deals Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale August 13, 2026 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, Yutthana Gaetgeaw PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several platforms. Amid the throes of bankruptcy, Sangamo Therapeutics has agreed to divest its Fabry disease program and a clutch of other assets and technolo…